non glp 1 drugs for weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans Non-Alc in the GLP-1 Era
Description
Rssner S, Sjostrom L, Noack R, Meinders AE, Noseda G

Many patients on semaglutide or tirzepatide consume far less than this because their appetite is so suppressed

Nature Communications

To view or add a comment, sign in Every Mechanism Has a Safety Story The more I study LDL-lowering drugs, the more I realize each one has its own safety story

Our team will also consider the presence of certain ailments, including nonalcoholic fatty liver disease, obstructive sleep apnea, hypertension, and type 2 diabetes

PLoS ONE 8 , e69010 (2013)
